FDA approves Fortress subsidiary Checkpoint's UNLOXCYT for advanced cSCC

Fortress Biotech, Inc.

FDA approved UNLOXCYT (cosibelimab-ipdl) for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) in adults not candidates for curative surgery/radiation.
UNLOXCYT is the first and only PD-L1 blocking antibody approved for this indication.
Approval based on objective response rates and duration of response from Study CK-301-101 (NCT03212404).
Checkpoint Therapeutics is a majority-controlled subsidiary of Fortress Biotech, Inc.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.